S&P 500 Industrials Sector SEC Filings — June 10, 2026

10-06-2026

Purebase Corporation announced the appointment of Dr. Amy T. Clemens as Chief Financial Officer, effective June 5, 2026. Dr. Clemens previously served as interim CFO for two years during the company's inception and returns from the defense industry. The filing does not disclose any financial metrics or performance data, so no period-over-period comparisons or quantitative trends are available.

• · Dr. Clemens previously served as interim CFO for 2 years during Purebase's inception before returning to the defense industry.
• · The appointment is effective June 5, 2026.
• · The company describes itself as a 'highly diversified mineral resource company' and a 'diversified resource company' that acquires, develops and markets high-value minerals and agricultural products.

10-06-2026

Corebridge Financial, Inc. (CRBG) provided an update on its merger with Equitable Holdings, Inc., announcing progress on leadership appointments and integration planning, with the transaction expected to close by end of 2026. The combined entity will create a full-scale retirement platform with $90+ billion in assets moving to AllianceBernstein, making it a $1 trillion platform, and is expected to be accretive day one with double-digit accretion by 2029. However, the company faces near-term headwinds from market volatility and lower alternative investment returns, with VII expected to be roughly consistent with Q1 2025 levels and full-year returns in the 1-2% range, below long-term expectations.

• · Leadership first three layers announced; wave two communications expected in coming weeks.
• · Proxy and regulatory filings completed domestically and internationally; FINRA process in flight.
• · Expense synergy pacing: 30% by end of year 1, 75% by end of year 2, remainder shortly after.
• · Revenue synergies include cross-selling Corebridge's fixed annuities and IUL through Equitable's wealth management channel and Equitable's VUL through Corebridge distribution.
• · Nippon Life will own over 15% of the new Equitable, with potential to partner on spread products for Japan.
• · Corebridge's 2025 origination of $55B was split equally among internal capabilities, BlackRock, and Blackstone.
• · Near-term headwinds include market volatility, geopolitical uncertainty, and disruptions in software and private credit.
• · Q2 2026 alternative returns expected lower than Q1 2026; VII expected roughly consistent with Q1 2026.
• · Full-year VII expected in 1-2% range, below long-term expectations.

10-06-2026

InMed Pharmaceuticals Inc. regained compliance with Nasdaq's minimum $1.00 bid price requirement after its closing bid price remained at or above $1.00 for 10 consecutive business days from May 19 to June 2, 2026. The company had previously received a deficiency notice on March 27, 2026, due to its share price falling below the threshold for 30 consecutive trading days. Nasdaq confirmed the matter is now closed, removing the immediate delisting risk.

• · The deficiency notice was received on March 27, 2026, covering the period from February 11, 2026 to March 26, 2026.
• · Compliance was regained as of June 3, 2026, based on the 10 business days ending June 2, 2026.
• · A press release announcing the compliance was issued on June 4, 2026.

10-06-2026

Pantages Capital Acquisition Corp (PGACU) filed an 8-K on June 10, 2026, announcing proposed amendments to its Third Amended and Restated Memorandum and Articles of Association to extend the deadline to complete a business combination. The proposal allows up to 12 monthly extensions from June 6, 2026, to June 6, 2027, providing a total of up to 30 months post-IPO. If no business combination is completed by the final deadline, the company will redeem public shares and dissolve.

• · The extension period runs from June 6, 2026 to June 6, 2027.
• · The company may extend up to 12 times, each by one month, for a total of up to 12 additional months.
• · If no business combination is completed by June 6, 2027, the company must cease operations, redeem public shares, and liquidate and dissolve.
• · Up to $100,000 of trust interest may be used for dissolution expenses before redemption proceeds are distributed to public shareholders.
• · Redemption price equals the aggregate amount in the trust account (including interest not previously released, less taxes and dissolution expenses) divided by the number of public shares outstanding.

10-06-2026

Aldeyra Therapeutics appointed Darlene Deptula-Hicks to its board of directors on June 9, 2026. Ms. Deptula-Hicks brings over 30 years of experience in public and private life sciences, including senior executive and CFO roles, and will support the company's progress toward potential commercialization of therapies for immune-mediated diseases. The filing does not disclose any financial results or performance metrics, so no period-over-period comparisons are available.

• · Ms. Deptula-Hicks currently serves as acting CFO of Normunity Inc., a clinical-stage cancer biotech.
• · She previously served as CFO of F-star Therapeutics, Inc.
• · Aldeyra's product candidates include RASP modulators ADX-248, ADX-246, and reproxalap (for dry eye disease and allergic conjunctivitis), and ADX-2191 (intravitreal methotrexate for primary vitreoretinal lymphoma and retinitis pigmentosa).

10-06-2026

Einride AB, a global leader in autonomous and electric freight, completed its business combination with Legato Merger Corp. III, approved by Legato shareholders on June 4, 2026. The transaction valued Einride at a pre-money equity value of approximately $1.35 billion and included an oversubscribed $113 million PIPE financing supported by new and existing investors. Einride's American depositary shares and warrants will begin trading on Nasdaq under the symbols "ENRD" and "ENRDW" on June 10, 2026.

• · Einride was founded in 2016.
• · The business combination was approved by Legato shareholders at an extraordinary general meeting on June 4, 2026.
• · The PIPE was supported by new and existing investors, including Stockholm-based EQT Ventures and a global asset management company based on the West Coast of the United States.
• · TD Cowen served as lead financial and capital markets advisor to Einride and lead placement agent on the PIPE.
• · BTIG, LLC served as capital markets advisor to Legato and as co-placement agent on the PIPE.
• · Legal counsel for Einride was provided by DLA Piper LLP (US), Advokatfirma DLA Piper Sweden KB, and Conyers Dill & Pearman LLP.
• · Legal counsel for Legato included Graubard Miller, Lindskog Malmström Advokatbyrå AB, and Appleby (Cayman) Ltd.
• · Greenberg Traurig, LLP served as legal counsel to the placement agents.
• · Einride serves customers across North America, Europe, and the Middle East.

10-06-2026

Metagenomi Therapeutics, Inc. (MGX) announced the resignation of board member Brian C. Thomas, Ph.D., effective June 9, 2026, with no disagreement cited. At the same time, the company held its 2026 annual meeting, where stockholders elected Juergen Eckhardt and Eric Bjerkholt as Class II directors and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2026. The meeting had a quorum of 19,116,207 shares (50.8% of outstanding shares), but the director elections saw significant broker non-votes (10,382,607) and relatively low 'for' votes, indicating potential shareholder disengagement.

• · The director election had 10,382,607 broker non-votes for both nominees, representing 54.3% of the quorum shares.
• · Eric Bjerkholt received 8,251,289 'for' votes (94.5% of votes cast excluding broker non-votes), while Juergen Eckhardt received 7,296,718 'for' votes (83.5% of votes cast excluding broker non-votes).
• · Ratification of PricewaterhouseCoopers LLP passed overwhelmingly with 18,483,295 'for' votes (99.7% of votes cast).
• · The record date for the annual meeting was April 13, 2026, and the proxy statement was filed on April 27, 2026.

10-06-2026

Trane Technologies announced the appointment of Donny Simmons as Chief Operating Officer, effective July 1, 2026, reporting to Chair and CEO Dave Regnery. The move aligns leadership structure with the company's increased scale and expanding market opportunities, as Trane has nearly doubled annual revenue since 2020. No negative or flat performance metrics were disclosed in this filing.

• · Simmons previously served as Group President of the Americas region, overseeing commercial and residential HVAC, transport refrigeration, and life science solutions.
• · Simmons joined the company in 2001 and has led Commercial HVAC North America, EMEA, and several global industrial businesses.
• · Simmons has experience across general management, sales, manufacturing, and finance.

10-06-2026

Getty Images Holdings, Inc. disclosed in a Form 425 filing that on June 9, 2026, a New York State Supreme Court issued a decision granting plaintiffs' motion for summary judgment in the Funicular Funds LP lawsuit. The court conditionally granted summary judgment as to certain warrants (subject to plaintiffs providing authorization letters by August 10, 2026), and plaintiffs sought $67,811,031 plus pre-judgment interest, which the company had already reserved against in its balance sheet reported in the May 11, 2026 Form 10-Q. However, the final judgment amount remains uncertain pending the court’s direction and potential appeals.

• · The lawsuit was originally filed on July 5, 2024 in New York State Supreme Court, New York County; Index No. 653410/2024.
• · The consolidated action generally alleges breaches of warrant agreements dated August 4, 2020.
• · Plaintiffs were given until August 10, 2026 to provide authorization letters for certain remaining warrants, after which the court will direct entry of judgment.
• · The company reserved the full $67,811,031 in its Condensed Consolidated Balance Sheet as of the May 11, 2026 Form 10-Q filing.
• · The company continues to caution that actual results could differ materially due to risks including AI-related legal/ethical issues, cybersecurity, and foreign currency fluctuations.

10-06-2026

LB Pharmaceuticals Inc announced that Chief Medical Officer Dr. Anna Eramo will resign effective June 15, 2026, for personal reasons, and transition to an advisor role through September 15, 2026. The company stated the departure is unrelated to clinical program operations and does not expect a material impact on clinical development activities or milestones. A search for a replacement is underway, and the company has experienced clinical teams to oversee ongoing trials.

• · Dr. Eramo will receive her current base salary on a monthly basis until June 15, 2027, if she remains engaged as a consultant through September 15, 2026.
• · She will receive 100% of her target annual bonus for 2026 on a prorated basis.
• · The company will reimburse COBRA healthcare premium costs for up to 12 months following the Separation Date.
• · The Separation Agreement includes confidentiality and non-disparagement covenants and a release of claims.

10-06-2026

M2i Global, Inc. received a termination notice from Volato Group, Inc. regarding their merger agreement dated July 28, 2025. M2i disputes the termination, rejects it as without merit, and intends to vigorously enforce its contractual rights, including seeking damages and equitable relief. The company cannot predict the ultimate outcome of this matter.

• · The merger agreement was dated July 28, 2025.
• · The termination notice was received on June 4, 2026.
• · Volato alleges termination is effective as of June 4, 2026, under Section 10.1 of the Merger Agreement.
• · M2i has notified Volato that it rejects the purported termination and considers the notice without merit.
• · M2i intends to pursue all available remedies, including damages and/or equitable relief.

10-06-2026

Syndax Pharmaceuticals held its 2026 Annual Meeting on June 10, 2026, where stockholders approved the 2026 Equity Incentive Plan (reserving 7,200,000 shares) and the 2026 Employee Stock Purchase Plan, both effective immediately. The 2026 Plan replaces the expired 2015 Omnibus Incentive Plan, and the 2026 ESPP does not carry over shares from the 2015 ESPP. All director nominees were elected, and all five proposals passed, though the 2026 Plan received a relatively narrow approval margin (33.3M for vs. 25.4M against).

• · The 2026 Plan includes share recycling provisions from the 2015 Plan's outstanding awards.
• · The 2026 ESPP has two components: a Section 423 qualified component for U.S. employees and a non-qualified component for foreign employees.
• · Shares available under the 2015 ESPP will not roll over to the 2026 ESPP.
• · The 2026 Plan received a relatively narrow approval with 33,333,263 votes for and 25,392,051 against (excluding broker non-votes).
• · All other proposals passed with strong majorities: advisory say-on-pay (55.7M for), auditor ratification (66.6M for), and 2026 ESPP (58.7M for).

10-06-2026

Aimco held its 2026 Annual Meeting on June 10, 2026, where stockholders elected all nine director nominees, ratified Grant Thornton LLP as independent auditor for fiscal 2026, and approved executive compensation on an advisory basis. All proposals passed with strong support, though broker non-votes accounted for approximately 10.7% of outstanding shares on director elections and the say-on-pay vote.

• · Record date for the meeting was April 22, 2026.
• · Broker non-votes totaled 15,408,377 on director elections and the say-on-pay proposal, representing about 10.7% of outstanding shares.
• · Ratification of Grant Thornton LLP as independent auditor received 122,448,341 votes for, 44,640 against, and 102,692 abstentions, with no broker non-votes.
• · The advisory vote on executive compensation received 105,737,910 for, 1,060,791 against, and 388,595 abstentions.

10-06-2026

On June 9, 2026, Amplitude, Inc. held its annual meeting of stockholders. All three Class II director nominees (Pat Grady, Curtis Liu, Catherine Wong) were elected, the appointment of KPMG LLP as independent auditor for fiscal year 2026 was ratified, and the compensation of named executive officers was approved on an advisory basis. The results show strong shareholder support for all proposals, with broker non-votes ranging from ~8% to ~9% of total shares.

• · All three Class II director nominees were elected to serve until the 2029 annual meeting.
• · Ratification of KPMG LLP as independent auditor passed with 190,036,610 votes for, 117,267 against, and 54,546 abstentions (no broker non-votes).
• · The advisory vote on named executive officer compensation passed with 172,928,572 votes for, 1,934,698 against, and 1,142,169 abstentions (14,202,984 broker non-votes).

10-06-2026

Prelude Therapeutics held its 2026 Annual Meeting on June 9, 2026, where stockholders approved the election of three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and approved the advisory vote on executive compensation. All proposals passed with strong shareholder support, with the auditor ratification receiving over 99.9% of votes cast in favor.

• · Director Krishna Vaddi received 26,996,820 votes for and 55,937 withheld.
• · Director Paul Scherer received 25,532,267 votes for and 1,520,490 withheld.
• · Director Katina Dorton received 26,998,601 votes for and 54,156 withheld.
• · Ratification of Ernst & Young LLP: 31,841,080 for, 4,951 against, 5,742 abstaining.
• · Advisory vote on executive compensation: 26,869,142 for, 107,500 against, 76,115 abstaining.
• · Advisory vote on frequency of say-on-pay: 1 year received 26,877,941 votes (most favored).
• · Broker non-votes were 4,799,016 for director elections and the say-on-pay proposals, and 0 for auditor ratification.

10-06-2026

IDEAYA Biosciences completed a public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares, raising net proceeds of approximately $323.6 million. The offering included full exercise of the underwriters' option for additional shares. The company entered into an underwriting agreement with several underwriters and agreed to a 60-day lock-up period for directors and executive officers.

• · The offering was made under an automatically effective shelf registration statement on Form S-3 (Registration No. 333-295560).
• · The company granted the underwriters a 30-day option to purchase up to 1,666,669 additional shares, which was exercised in full.
• · The lock-up agreement restricts the company and its directors and executive officers from selling or transferring common stock for 60 days after the prospectus date, subject to certain exceptions.
• · The pre-funded warrants are exercisable from issuance until fully exercised, subject to an ownership limitation.

10-06-2026

enGene Therapeutics Inc. held its 2026 Annual General Meeting on June 9, 2026, with 56,196,302 common shares represented (83.89% of outstanding). All director nominees were elected with overwhelming support (over 99% of votes cast), and the appointment of the auditor was approved with 56,180,287 votes for and only 16,015 against. No negative or flat metrics were present.

• · The meeting was held on June 9, 2026 at 8:30 a.m. EDT.
• · Record date for voting was April 28, 2026.
• · All director nominees were elected with over 99% of votes cast in favor.
• · Auditor appointment received 56,180,287 votes for and only 16,015 against, with no broker non-votes.

10-06-2026

MP Materials Corp. held its 2026 Annual Meeting on June 9, 2026, where stockholders elected two Class III directors (Arnold W. Donald and Randall J. Weisenburger) to serve until the 2029 annual meeting, approved on an advisory basis the compensation of named executive officers, and ratified KPMG LLP as the independent auditor for fiscal 2026. While director elections and auditor ratification passed with strong support, the advisory vote on executive compensation received approximately 22.7% votes against, indicating notable shareholder dissent.

• · Broker non-votes totaled 38,838,978 shares on Proposals One and Two, indicating significant shares not voted on director elections and executive compensation.
• · Proposal Three (auditor ratification) had no broker non-votes, with 129,305,494 votes FOR and only 858,587 AGAINST.
• · The two elected Class III directors received 78,024,548 and 74,725,578 votes FOR, respectively.
• · Continuing directors include Connie K. Duckworth, Maryanne R. Lavan, James H. Litinsky, Andrew A. McKnight, and General (Retired) Richard B. Myers.

10-06-2026

M3-Brigade Acquisition V Corp. filed a DEFA14A on June 10, 2026, providing additional proxy materials regarding its proposed business combination with ReserveOne, a crypto-focused entity. The filing includes forward-looking statements and risk factors, but no specific financial figures or quantitative data are disclosed. The company urges shareholders to read the definitive proxy statement/prospectus filed on May 13, 2026.

• · Definitive proxy statement/prospectus was filed with the SEC on May 13, 2026.
• · Shareholders of record as of May 7, 2026 are entitled to vote.
• · The business combination involves a crypto-related business, with risks including volatility of cryptocurrencies and regulatory uncertainty.
• · The company's final prospectus was dated July 31, 2024 and filed on August 2, 2024.
• · Pubco's Form S-4 was filed on December 5, 2025.

10-06-2026

Dell Technologies Inc. entered into a $6.0 billion credit agreement on June 10, 2026, with JPMorgan Chase Bank as administrative agent and a syndicate of lenders including Bank of America, Barclays, Citibank, Goldman Sachs, Wells Fargo, and HSBC. The facility includes a $500 million letter of credit sublimit and is structured with pricing tied to Dell's credit ratings, ranging from 0.825% to 1.450% for Term SOFR loans and 0.065% to 0.240% for the unused line fee. The agreement also contains a consolidated interest coverage ratio covenant and other standard terms, but no period-over-period comparisons are available as this is a new facility.

• · The credit agreement is dated June 10, 2026, and includes Dell International L.L.C. and EMC Corporation as borrowers.
• · The facility has a pricing grid based on debt ratings from S&P, Moody's, and Fitch, with five pricing levels ranging from Level 1 (≥ BBB+/Baa1/BBB+) to Level 5 (≤ BB/Ba2/BB).
• · The Term SOFR Applicable Rate ranges from 0.825% (Level 1) to 1.450% (Level 5); the Base Rate ranges from 0.000% (Levels 1-2) to 0.450% (Level 5); the Unused Line Fee ranges from 0.065% (Level 1) to 0.240% (Level 5).
• · The agreement includes a consolidated interest coverage ratio covenant (Article VII, Section 7.03) and standard events of default (Article VIII).
• · The facility is arranged by JPMorgan Chase, Bank of America, Barclays, Citibank, Goldman Sachs, Wells Fargo, and HSBC as joint lead arrangers and joint bookrunners.

10-06-2026

Fifth Third Bancorp completed exchange offers and consent solicitations on June 10, 2026, exchanging approximately $1.273B of existing Comerica/FTFC notes for new Fifth Third notes and cash. The exchange saw strong participation: 60.9% of the 4.000% Senior Notes due 2029 ($334.8M of $550M) and 93.8% of the 5.982% Fixed-to-Floating Rate Senior Notes due 2030 ($938.2M of $1.0B) were tendered. However, $215.2M of the 4.000% notes and $61.8M of the 5.982% notes remain outstanding and will continue under amended indentures with reduced covenants.

• · The exchange offers expired at 5:00 p.m. New York City time on June 8, 2026.
• · All accepted Existing FTFC Notes will be retired and cancelled.
• · The Proposed Amendments deleted certain covenants, including Events of Default (clauses 4 and 7), consolidation restrictions, existence, maintenance of properties, payment of taxes, and conditions to defeasance.
• · New Fifth Third 4.000% Senior Notes due 2029 mature February 1, 2029, and are redeemable on or after November 3, 2028 at 100% of principal plus accrued interest.
• · New Fifth Third 5.982% Fixed-to-Floating Rate Senior Notes due 2030 mature January 30, 2030; interest is fixed at 5.982% until January 30, 2029, then floats at Compounded SOFR plus 2.155%.
• · The New Fifth Third Notes are unregistered and may only be offered under exemptions from registration.
• · Fifth Third entered into a Registration Rights Agreement with J.P. Morgan Securities LLC, agreeing to file a registration statement within 365 days of the Final Settlement Date.
• · If Fifth Third fails to comply with registration obligations, it must pay additional interest on the New Fifth Third Notes.

10-06-2026

Broadridge Financial Solutions appointed Todd Diganci to its Board of Directors effective August 1, 2026, expanding the board to 10 members, eight of whom are independent. Diganci, former EVP, CFO, and CAO of FINRA, will serve on the Audit Committee. The appointment brings regulatory and financial expertise to support Broadridge's innovation and growth.

• · Broadridge processes over 7 billion communications annually and underpins daily average trading of over $15 trillion in tokenized and traditional securities globally.
• · Broadridge is part of the S&P 500 Index and employs over 15,000 associates in 21 countries.

10-06-2026

Bark, Inc. filed its 10-K for the fiscal year ended March 31, 2026, reporting total revenue of $394.8M, down 18.5% from $484.2M in FY2025, driven by a 21.9% decline in Direct-to-Consumer (DTC) revenue to $324.9M. The company narrowed its net loss to $39.0M from $32.9M in the prior year, a 18.6% increase in net loss, while gross margin improved to 61.3% from 62.4%. Total orders fell 23.8% to 10.06 million from 13.21 million, though average order value remained nearly flat at $31.06.

• · DTC gross margin improved to 68.4% in FY2026 from 66.1% in FY2025.
• · Commerce gross profit declined 9.7% YoY to $28.1M.
• · Shipping and fulfillment expense decreased 14.1% YoY to $119.4M.
• · Advertising and marketing as a percentage of revenue fell to 15.0% from 17.3%.
• · General and administrative expense as a percentage of revenue increased to 56.4% from 52.3%.
• · Interest income dropped 61.8% YoY to $1.9M.
• · Interest expense decreased 33.4% YoY to $1.9M.
• · Other income, net surged 768.2% YoY to $1.1M.
• · Commerce revenue grew 2.3% YoY, partially offsetting DTC decline.
• · Total orders fell 23.8% YoY, while average order value remained essentially flat at $31.06.

10-06-2026

Slide Insurance Holdings, Inc. held its Annual Meeting of Stockholders on June 10, 2026, where shareholders elected three Class I directors (Robert Gries, Andrew Wright, and Beth W. Bruce) and ratified the selection of Forvis Mazars, LLP as the independent auditor for fiscal year 2026. All proposals passed with strong shareholder support, though director Andrew Wright received a notable 9,990,367 withheld votes (11.96% of votes cast), indicating some shareholder dissent.

• · Total votes for Proposal 1: Robert Gries received 80,945,212 votes for, 2,549,557 withheld; Andrew Wright received 73,504,402 for, 9,990,367 withheld; Beth W. Bruce received 74,191,861 for, 9,302,908 withheld.
• · Broker non-votes for all director nominees were 11,727,479.
• · Proposal 2 (auditor ratification) passed with 93,541,941 votes for, 12,985 against, and 1,667,322 abstentions.
• · The annual meeting was held on June 10, 2026, and the filing was made the same day.

10-06-2026

Biogen Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, where all ten director nominees were elected, the appointment of PricewaterhouseCoopers LLP as independent auditor for FY2026 was ratified, and the advisory vote on executive compensation was approved. While most directors received strong support (over 120 million votes for several nominees), Eric K. Rowinsky received only 93.6 million votes for (76.8%) with 28.2 million against, indicating notable shareholder dissent. The advisory say-on-pay vote passed with 114.2 million for (93.7% of votes cast), but 7.5 million votes were against.

• · Total outstanding shares eligible to vote not disclosed; broker non-votes were 9,359,127 on all director elections and the say-on-pay proposal.
• · The auditor ratification did not have broker non-votes; total votes cast were 131,266,549.
• · Eric K. Rowinsky received the lowest support among directors with 93,569,685 votes for and 28,216,589 against (23.2% against).
• · Lloyd Minor received the highest support with 121,220,738 votes for (99.5% of votes cast).

10-06-2026

Genco Shipping & Trading Limited (NYSE: GNK) filed a DEFA14A on June 10, 2026, urging shareholders to vote for all of its six highly qualified directors on the WHITE proxy card and to reject Diana Shipping Inc.'s inadequate $24.80 tender offer, which is below Genco's underlying net asset value (NAV) and provides no control premium. The filing highlights that all three proxy advisory firms (ISS, Glass Lewis, Egan-Jones) recommend voting for Genco's directors, while Diana's nominees are criticized for ties to value destruction and lack of independence. Genco's Board emphasizes its Comprehensive Value Strategy has delivered large and growing dividends and superior returns, but the filing does not provide specific financial metrics or period-over-period comparisons.

• · Genco's fleet consists of 43 vessels with an average age of 12.6 years and aggregate capacity of approximately 4,935,000 dwt.
• · Diana initially nominated four additional nominees but withdrew them after proxy advisory firms recommended Genco's directors.
• · Jens Ismar led Western Bulk into bankruptcy as CEO; Paul Cornell received a withhold recommendation from ISS for his service on Excel Maritime's board.
• · Genco's Board recommends continuation of the shareholder rights plan to prevent a creeping takeover by Diana.
• · The filing does not provide any financial results, dividend amounts, or period-over-period comparisons.

10-06-2026

Dream Finders Homes, Inc. completed its reincorporation from Delaware to Texas, effective June 9, 2026, converting from a Delaware corporation to a Texas corporation under the same name. The company's authorized capital stock remains 355,000,000 shares, consisting of 350,000,000 shares of Common Stock (289,000,000 Class A and 61,000,000 Class B) and 5,000,000 shares of Preferred Stock (including 150,000 Series A Convertible Preferred). The reincorporation does not change the company's principal business address in Jacksonville, Florida, or its operational structure.

• · The reincorporation was effective at 5:00 p.m. Eastern Time on June 9, 2026.
• · The registered office in Texas is at 1999 Bryan St., Suite 900, Dallas, Texas 75201, with CT Corporation System as registered agent.
• · Class B Common Stock carries 3 votes per share (based on conversion into Class A), while Class A Common Stock carries 1 vote per share.
• · Class B Common Stock is convertible at any time into Class A Common Stock on a 1:1 basis.
• · The certificate of formation allows shareholders holding a majority of voting power to approve fundamental business transactions without a separate class vote, unless preferred stock rights specify otherwise.
• · In a change of control transaction, Class A and Class B holders must be treated equally unless a majority of the affected class votes for different treatment.

10-06-2026

Barinthus Biotherapeutics plc filed a DEF 14A proxy statement for its Annual General Meeting to be held on July 2, 2026. The Board recommends voting FOR all seven proposals, including re-election of directors Karen T. Dawes and Anne M. Phillips, re-appointment of PricewaterhouseCoopers LLP as auditors, and approval of the directors' compensation report. The record date for ordinary shareholders is June 30, 2026, and for ADS holders is June 10, 2026.

• · Meeting date: July 2, 2026
• · Record date for ordinary shareholders: June 30, 2026 (6:30 p.m. London Time)
• · Record date for ADS holders: June 10, 2026 (5:00 p.m. Eastern Time)
• · Quorum requirement: at least 33 1/3% of issued shares entitled to vote
• · Proxies for ordinary shareholders must be received by 2:30 p.m. London Time on June 30, 2026
• · ADS voting deadline: 12:00 p.m. Eastern Time on June 26, 2026
• · Board recommends FOR all seven proposals

10-06-2026

BancFirst Corporation announced the acquisition of SpiritBank, a privately held community bank in Tulsa, Oklahoma, on June 10, 2026. The acquisition adds approximately $939.6 million in total assets, $618.4 million in loans, and $847.2 million in deposits. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary conditions, and Spirit will operate under its present name until merged into BancFirst.

• · The filing was made under Item 7.01 Regulation FD Disclosure.
• · SpiritBank is headquartered in Tulsa, Oklahoma.
• · Spirit will retain its name until merged into BancFirst.
• · The closing is in Q4 2026.

10-06-2026

American Eagle Outfitters Inc. entered into Amendment No. 2 to its Second Amended and Restated Credit Agreement, effective June 4, 2026, with unanimous lender consent. The amendment extends the maturity date to the fifth anniversary of the amendment's effective date (approximately June 2029) and makes other modifications to the existing credit facility. No financial terms or new borrowing amounts were disclosed in the filing.

• · The amendment was unanimously approved by 100% of the lenders immediately prior to the effective date.
• · The maturity date is extended to the fifth anniversary of the Amendment No. 2 Effective Date (June 4, 2026), i.e., approximately June 4, 2029.
• · The amendment includes reaffirmation of existing liens and security interests by both U.S. and Canadian loan parties.
• · Post-closing requirements include delivery of flood hazard determinations and related documentation within 90 days of the effective date.
• · The amendment is governed by New York law.

10-06-2026

Fennec Pharmaceuticals held its annual meeting on June 10, 2026, where shareholders approved all proposals. All five director nominees were elected, and the independent auditor Haskell & White LLP was ratified overwhelmingly (99.4% in favor). However, support for the say-on-pay resolution (94.4% in favor) and the 2020 Equity Incentive Plan amendments (92.4% in favor) was strong but slightly lower, while the 2026 Equity Inducement Plan received 94.7% approval.

• · Shareholders approved an advisory vote on the frequency of future say-on-pay votes, with 18,235,648 votes for every year, 2,326 for two years, and 2,086,219 for three years.
• · The 2020 Equity Incentive Plan amendment vote excluded 766,153 shares held by officers and directors from the FOR count.
• · All five director nominees received between 20.1 million and 20.3 million votes in favor, with broker non-votes of 5.88 million on each.

10-06-2026

Light & Wonder, Inc. filed a Form 8-K on June 10, 2026, furnishing the script for its 2026 annual meeting of stockholders. The filing includes forward-looking statements and non-GAAP financial measures, with reconciliations available in the Q1 2026 Earnings Presentation. No specific financial results or material changes were disclosed in this filing.

• · The annual meeting was scheduled for 4:00 p.m. PDT on June 10, 2026 (9:00 a.m. AEST on June 11, 2026).
• · The filing is a Regulation FD Disclosure under Item 7.01 and includes Exhibit 99.1 (Annual Meeting Script).
• · Non-GAAP financial measures in the script are reconciled in the Appendix to the Q1 2026 Earnings Presentation on the company's website.

10-06-2026

On June 8, 2026, DeFi Development Corp. announced the resignation of Parker White as Chief Operating Officer and Chief Investment Officer. The company entered into a separation agreement providing $250,000 in cash payments over twelve months and accelerated vesting of 213,272 unvested stock options, while also engaging Mr. White for consulting services at $8,333 per month.

• · The Separation Agreement includes a release of claims against the company.
• · Mr. White's consulting services will focus on transition of operations of certain validators owned by the company.
• · The effective date of resignation and separation is June 8, 2026.
• · The filing is dated June 10, 2026.

10-06-2026

Clover Health Investments announced that on June 9, 2026, CMS recalculated its 2026 Star Rating for Contract H5141 (PPO plan) to 4.5 Stars, up from 3.5 Stars, following a court order. The 4.5 Star rating covers over 97% of Clover’s members, while its HMO plan (Contract H8010) remains at 4.0 Stars. This positive regulatory outcome is expected to enhance Clover’s revenue and competitive position for Payment Year 2027.

• · The lawsuit was filed in the United States District Court for the Southern District of Georgia (Case No. 2:25-CV-142).
• · The court entered final judgment on May 29, 2026, granting partial summary judgment for Clover.
• · The 4.5 Star rating applies to Payment Year 2027.
• · Clover has been instructed by CMS to submit alternate bids at the 4.5 Star level.
• · The HMO plan’s 2026 Star Rating remains unchanged at 4.0 Stars.

10-06-2026

Ambarella, Inc. filed definitive additional proxy materials urging shareholders to vote FOR Proposal No. 4 at the 2026 Annual Meeting on June 26, 2026, which seeks approval to increase the shares available under the 2021 Equity Incentive Plan by 2,750,000 shares. The company highlights its business transformation into edge AI SoCs, record revenue of $390.7 million in fiscal year 2026, and strong shareholder support for its compensation program (93% Say-on-Pay in 2025). However, the filing also notes that the three-year average gross burn rate declined from 4.4% to 3.07% and overhang declined from 10.2% to 8.13%, indicating disciplined equity usage but still a need for additional shares to sustain talent retention and growth.

• · The company shipped 45 million edge AI SoCs and supports more than 200 AI model architectures.
• · Approximately 75% of employees work in R&D, mostly software engineers.
• · In FY2026, employees below executive officer level received approximately 89% of equity award shares granted.
• · CEO's target total direct compensation is 84% equity; other NEOs average 80% equity.
• · Three-year average gross burn rate declined from 4.4% (FY2021) to 3.07% (FY2026).
• · Overhang declined from 10.2% to 8.13% over the same period.
• · Say-on-Pay support: 93% in 2025, 88% in 2024, 89% in 2023.
• · The proposed share increase is expected to cover needs for approximately two years.
• · The company competes for talent with some of the world's largest companies, especially in Silicon Valley.

10-06-2026

Medallion Financial Corp. filed an 8-K on June 10, 2026, announcing the preliminary results from its 2026 Annual Meeting of Stockholders via a press release. The filing does not disclose any financial results or performance metrics, only the procedural outcome of the meeting.

• · The press release (Exhibit 99.1) is incorporated by reference but not summarized in the filing.
• · No financial results, revenue, earnings, or operational metrics were disclosed in this 8-K.

10-06-2026

Abacus Global Management, Inc. filed an 8-K on June 10, 2026, furnishing a shareholder letter as a press release under Regulation FD. The filing contains no financial results or operational metrics, only a disclosure of the letter attached as Exhibit 99.1.

• · The filing is under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• · The shareholder letter was distributed as a press release on June 10, 2026.
• · The company's common stock trades under symbol ABX on the NYSE, and its 9.875% Fixed Rate Senior Notes due 2028 trade under symbol ABXL on the NYSE.
• · The company is not an emerging growth company.

10-06-2026

Dakota Community Bank & Trust NA filed its 13F-HR for the quarter ending March 31, 2026, reporting a portfolio value of approximately $295.6 million across 96 holdings. The largest positions include Tesla (12,235 shares, $4.55M), Microsoft (3,139 shares, $1.16M), and Nvidia (6,304 shares, $1.10M). The filing shows a concentrated equity portfolio with significant exposure to large-cap technology and energy stocks, but no prior quarter comparison is available to assess performance trends.

• · The portfolio includes a leveraged ETF position: Direxion Daily TSLA Bull 2X Shares (23,297 shares, $283,059).
• · Tesla is the largest single stock position by value at $4.55M (12,235 shares), with a significant portion (11,601 shares) held in the Direxion leveraged ETF.
• · The bank holds 96 positions with a total market value of $295.6M as of March 31, 2026.
• · No prior quarter comparison data is available in this filing to assess changes in holdings.
• · The portfolio is diversified across sectors including technology, energy, financials, healthcare, and consumer goods.

10-06-2026

US Asset Management LLC filed its 13F-HR for the quarter ending March 31, 2026, disclosing a portfolio of 117 equity securities with a total market value of approximately $115,416 million. The top holdings include Apple Inc. ($9,324 million), NVIDIA Corp ($9,047 million), Alphabet Inc. Class A ($6,299 million), Microsoft Corp ($6,078 million), and Amazon.com Inc ($4,477 million). The report reflects a diversified portfolio with significant weight in technology and large-cap growth stocks.

• · The 13F-HR filing reflects holdings as of market close on March 31, 2026.
• · All reported securities are held with sole voting and dispositive power, indicating direct ownership without shared arrangements.
• · The portfolio includes a mix of large-cap tech (e.g., NVIDIA, Apple, Microsoft, Amazon, Alphabet), financials (JPMorgan Chase, Goldman Sachs), healthcare (AbbVie, Eli Lilly, Merck), and industrial/conglomerate stocks.
• · Notable positions include Intel (15,090 shares), Bank of America (31,631 shares), and ProShares Trust (14,626 shares), showing significant exposure to semiconductors and financials.

10-06-2026

TriLinc Global Impact Fund, LLC reported a portfolio of approximately $283 million as of May 31, 2026, with a weighted average loan size of $10 million and a short weighted average duration of 0.4 years. The company has funded $1.210 billion in aggregate investments to 103 borrower companies globally, supporting 43,572 permanent employees, and has received $905.7 million in full aggregate transaction repayments (75% of total invested). The filing provides a portfolio update but does not include any period-over-period comparisons or financial performance metrics, limiting the ability to assess growth or decline.

• · Weighted average duration of the portfolio is 0.4 years.
• · Aggregate investments include $104.7 million in temporary investments.
• · Repayments of $905.7 million represent 75% of total invested amount.

10-06-2026

J.P. Morgan Chase Commercial Mortgage Securities Corp. issued $648,862,000 in public certificates and private certificates for the JPMF1 Multifamily Mortgage Trust 2026-FX1, backed by 17 multifamily mortgage loans. The net proceeds to the registrant were approximately $656,510,249 after expenses of $6,367,170. The retaining sponsor satisfied its credit risk retention obligation by purchasing risk retention certificates with an aggregate fair value of approximately $37,379,615, representing 5.08% of the aggregate fair value of all certificates (excluding Class R), exceeding the required 5.00% threshold.

• · The registration statement (file no. 333-280318) was originally declared effective on September 9, 2024.
• · The public certificates were sold to underwriters including J.P. Morgan Securities LLC, ATLAS SP Securities, Goldman Sachs & Co. LLC, and Santander US Capital Markets LLC.
• · The private certificates (excluding risk retention certificates) were sold to the same four firms as initial purchasers in a transaction exempt from registration under Section 4(a)(2) of the Securities Act.
• · The risk retention certificates were sold to MF1 REIT III FR Retention Holder LLC, a majority-owned affiliate of MF1.
• · Legal and tax opinions were rendered by Cadwalader, Wickersham & Taft LLP and are attached as exhibits.
• · There are no material differences between the valuation methodology and key inputs used in the preliminary prospectus and those used at closing.

10-06-2026

Graybar Electric Company, Inc. held its Annual Meeting of Shareholders on June 10, 2026, at which the entire Board of Directors was re-elected. The filing confirms the shareholder vote outcome but provides no financial results or operational metrics.

• · The Board of Directors was re-elected in its entirety at the June 10, 2026 Annual Meeting.
• · No specific vote tallies or shareholder proposals were disclosed in this filing.

10-06-2026

Deep Fission, Inc. filed an S-1/A registration statement on June 10, 2026, for its initial public offering. The filing discloses that the company's previously issued financial statements for fiscal year 2024 and certain interim periods in 2023-2025 can no longer be relied upon due to material accounting errors related to SAFE Note valuations and stock-based compensation expense, and that management has concluded disclosure controls and procedures were not effective as of March 31, 2026 due to material weaknesses in internal control over financial reporting. The company is a pre-revenue nuclear reactor developer with no commercial operations and faces significant going concern risks.

• · The company concluded that audited financial statements for FY2024 and for the period from July 17, 2023 (inception) through December 31, 2023, and unaudited statements for six-month periods ended June 30, 2024 and 2025, and three- and nine-month periods ended September 30, 2024 and 2025, could no longer be relied upon.
• · Material accounting errors identified were related to valuations of Simple Agreement for Future Equity (SAFE Notes) and stock-based compensation expense.
• · Management concluded disclosure controls and procedures were not effective as of March 31, 2026 due to material weaknesses in internal control over financial reporting.
• · The company is a pre-revenue company with no commercial operations and faces significant risks including ability to continue as a going concern.
• · The company plans to list its common stock on Nasdaq but must maintain such listing.